Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 68
Selected: 0
NCT IDTitle
NCT06435156Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
NCT02300363DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
NCT01677910TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
NCT02026063Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
NCT02373046Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets
NCT00903383Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate
NCT02459899Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
NCT01494233A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
NCT00962065Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
NCT01334242A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects
NCT06203002A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT01441232A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
NCT01456052A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
NCT00691808Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment
NCT03910387Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
NCT00813098Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
NCT02157584An Open-Label Food Effect Study of Telotristat Etiprate
NCT02300350DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
NCT03332771Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
NCT01104415Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
NCT03242018A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
NCT05696366Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
NCT01913002Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects
NCT00853047Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
NCT03315143Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
NCT02063659Telotristat Etiprate for Carcinoid Syndrome Therapy
NCT03302845A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
NCT02647918Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function
NCT01417052A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis
NCT01818232Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects
NCT01916850Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects
NCT03242252Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
NCT01555008Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment
NCT04455633Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
NCT03285594Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
NCT03066830Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
NCT04034745Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
NCT03386344Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
NCT02531035A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
NCT02471274PK Study of Sotagliflozin in Subjects With Hepatic Impairment
NCT01528111Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
NCT06481891A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT01916863Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects
NCT00847886Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis
NCT01742208Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
NCT01411800An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
NCT01188863Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus
NCT03423446Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
NCT06933056Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
NCT02494609Oral Contraceptive DDI Study